HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/6/H2425    most recent 01045.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Morimoto, A. Articles by Cheng, C.-P. Search for Related Content PubMed PubMed Citation Articles by Morimoto, A. Articles by Cheng, C.-P.

Endogenous ₃-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure

Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1045

Submitted 18 November 2003 ; accepted in final form 6 February 2004

The objective of the present study was to test the hypothesis that endogenous ₃-adrenoreceptor (AR) activation contributes to left ventricular (LV) and cardiomyocyte dysfunction in heart failure (CHF). Stimulation of the ₃-AR inhibits cardiac contraction. In the failing myocardium, ₃-ARs are upregulated, suggesting that stimulation of ₃-ARs may contribute to depressed cardiac performance in CHF. We assessed the functional significance of endogenous ₃-AR activation in 10 conscious dogs before and after pacing-induced CHF. Under normal conditions, L-748,337, a specific ₃-AR antagonist, produced a mild increase in LV contractile performance assessed by the slope (E_es) of the LV pressure-volume relation (18%, 6.2 ± 0.9 vs. 7.3 ± 1.2 mmHg/ml, P < 0.05) and the improved LV relaxation time constant (; 28.4 ± 1.9 vs. 26.8 ± 1.0 ms, P < 0.05). After CHF, the plasma norepinephrine concentration increased eightfold, and L-748,337 produced a larger increase in E_es (34%, 3.8 ± 0.7 vs. 5.1 ± 0.8 mmHg/ml, P < 0.05) and a greater decrease in (46.4 ± 4.2 vs. 41.0 ± 3.9 ms, P < 0.05). Similar responses were observed in isolated myocytes harvested from LV biopsies before and after CHF. In the normal myocyte, L-748,337 did not cause significant changes in contraction or relengthening. In contrast, in CHF myocytes, L-748,337 produced significant increases in contraction (5.8 ± 0.9 vs. 6.8 ± 0.9%, P < 0.05) and relengthening (33.5 ± 4.2 vs. 39.7 ± 4.0 µm/s, P < 0.05). The L-748,337-induced myocyte response was associated with improved intracellular Ca²⁺ concentration regulation. In CHF myocytes, nadolol caused a decrease in contraction and relengthening, and adding isoproterenol to nadolol caused a further depression of myocyte function. Stimulation of ₃-AR by endogenous catecholamine contributes to the depression of LV contraction and relaxation in CHF.

endogenous catecholamine; ventricular and myocyte function; Ca²⁺ regulation

This article has been cited by other articles:

				F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, and J. Butler The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1747 - 1762. [Abstract] [Full Text] [PDF]

				B. Rozec, M. Erfanian, K. Laurent, J.-N. Trochu, and C. Gauthier Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1532 - 1538. [Abstract] [Full Text] [PDF]

				S. Masutani, H.-J. Cheng, M. Hyttila-Hopponen, J. Levijoki, A. Heikkila, A. Vuorela, W. C. Little, and C.-P. Cheng Orally Available Levosimendan Dose-Related Positive Inotropic and Lusitropic Effect in Conscious Chronically Instrumented Normal and Heart Failure Dogs J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 236 - 247. [Abstract] [Full Text] [PDF]

				L. Groban and J. Butterworth Perioperative management of chronic heart failure. Anesth. Analg., September 1, 2006; 103(3): 557 - 575. [Abstract] [Full Text] [PDF]